IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
LG Life Sciences 2007 Obesity drug
discovery
Terms of Agreement
Based on LG Life Sciences’ obesity
program, the company will use its
capabilities in drug discovery including
medicinal chemistry and pharmacological
evaluation; Takeda responsible for
subsequent R&D and commercialization.
Takeda will have exclusive rights to
selected compounds ww excluding South
Korea and Vietnam, with semi-exclusive
rights in India. In return, Takeda make
upfront, research and milestones of over
$100m in addition to royalties on resultant
products. In 2008 agreement ongoing and
candidates being screened for clinical
development.
Biowa 2007 Antibody discovery Agreement which provides Takeda with
access to Biowa’s (part of Kyowa Hakko)
patented Potelligent Technology platform
for the development of
antibody-dependent cellular cytotoxicity
(ADCC) enhanced antibodies.
XOMA 2007 Antibody discovery Agreement amended to increase number
of antibody discovery projects with
Takeda. Xoma earned $8m so far (in 4
months since start of collaboration) and
estimates total R&D funding and
payments could reach $230m over the
course of the amended agreement.
Confirmed ongoing in 2008 and expanded
to grant Takeda access to multiple
antibody technologies, paying Xoma a
$29m expansion fee.
Archemix 2007 Drug discovery for
three undisclosed
disease indications
© 2009 IMS Health In cor po rated or its af fil i ates Page 100
Agreement to collaborate on the
discovery, development and
commercialization of aptamer based
therapeutics. Takeda granted exclusive
rights for global R&D, manufacturing and
commercialization of resultant products in
return for $6m upfront, research funding,
milestone and royalty payments on
worldwide sales of aptamers
commercialized by Takeda. Discovery
phase evaluations are under way in the
USA.